Atyr Pharma Inc. (NASDAQ:LIFE) shares shot up 4.5% during trading on Wednesday . The stock traded as high as $3.05 and last traded at $3.01, with a volume of 91,272 shares. The stock had previously closed at $2.88.

Several brokerages recently commented on LIFE. William Blair downgraded shares of Atyr Pharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. BMO Capital Markets began coverage on shares of Atyr Pharma in a research note on Monday, April 11th. They issued a “market perform” rating on the stock. Finally, Zacks Investment Research raised shares of Atyr Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $23.75.

The stock’s 50-day moving average price is $2.84 and its 200 day moving average price is $3.99. The company’s market cap is $72.48 million.

Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.02. On average, analysts predict that Atyr Pharma Inc. will post ($2.79) earnings per share for the current year.

In other news, insider Grove Matsuoka bought 12,412 shares of the stock in a transaction dated Wednesday, May 11th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $37,732.48. Following the transaction, the insider now owns 2,412 shares of the company’s stock, valued at $7,332.48. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.